These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. A new model for nonalcoholic steatohepatitis in the rat utilizing total enteral nutrition to overfeed a high-polyunsaturated fat diet. Baumgardner JN; Shankar K; Hennings L; Badger TM; Ronis MJ Am J Physiol Gastrointest Liver Physiol; 2008 Jan; 294(1):G27-38. PubMed ID: 17947452 [TBL] [Abstract][Full Text] [Related]
3. Reversal of hepatic steatosis by omega-3 fatty acids measured non-invasively by (1) H-magnetic resonance spectroscopy in a rat model. Marsman HA; Heger M; Kloek JJ; Nienhuis SL; van Werven JR; Nederveen AJ; Ten Kate FJ; Stoker J; van Gulik TM J Gastroenterol Hepatol; 2011 Feb; 26(2):356-63. PubMed ID: 21261727 [TBL] [Abstract][Full Text] [Related]
4. The therapeutic potential of long-chain omega-3 fatty acids in nonalcoholic fatty liver disease. Shapiro H; Tehilla M; Attal-Singer J; Bruck R; Luzzatti R; Singer P Clin Nutr; 2011 Feb; 30(1):6-19. PubMed ID: 20619513 [TBL] [Abstract][Full Text] [Related]
5. Nonalcoholic hepatic steatosis in Zucker diabetic rats: spontaneous evolution and effects of metformin and fenofibrate. Forcheron F; Abdallah P; Basset A; del Carmine P; Haffar G; Beylot M Obesity (Silver Spring); 2009 Jul; 17(7):1381-9. PubMed ID: 19553925 [TBL] [Abstract][Full Text] [Related]
6. Fatty liver: role of inflammation and fatty acid nutrition. Byrne CD Prostaglandins Leukot Essent Fatty Acids; 2010; 82(4-6):265-71. PubMed ID: 20189787 [TBL] [Abstract][Full Text] [Related]
7. Fatty acid omega- and (omega-1)-hydroxylation in experimental alcoholic liver disease: relationship to different dietary fatty acids. Amet Y; Adas F; Nanji AA Alcohol Clin Exp Res; 1998 Oct; 22(7):1493-500. PubMed ID: 9802534 [TBL] [Abstract][Full Text] [Related]
8. Activation of peroxisome proliferator-activated receptor alpha by dietary fish oil attenuates steatosis, but does not prevent experimental steatohepatitis because of hepatic lipoperoxide accumulation. Larter CZ; Yeh MM; Cheng J; Williams J; Brown S; dela Pena A; Bell-Anderson KS; Farrell GC J Gastroenterol Hepatol; 2008 Feb; 23(2):267-75. PubMed ID: 17868330 [TBL] [Abstract][Full Text] [Related]
9. Suppression of hepatic fatty acid synthase by feeding alpha-linolenic acid rich perilla oil lowers plasma triacylglycerol level in rats. Kim HK; Choi S; Choi H J Nutr Biochem; 2004 Aug; 15(8):485-92. PubMed ID: 15302084 [TBL] [Abstract][Full Text] [Related]
10. Review article: omega-3 fatty acids - a promising novel therapy for non-alcoholic fatty liver disease. Masterton GS; Plevris JN; Hayes PC Aliment Pharmacol Ther; 2010 Apr; 31(7):679-92. PubMed ID: 20415840 [TBL] [Abstract][Full Text] [Related]
11. Treatment with exendin-4 improves the antidiabetic efficacy and reverses hepatic steatosis in glucokinase activator treated db/db mice. Dhanesha N; Joharapurkar A; Shah G; Kshirsagar S; Patel V; Patel K; Bahekar R; Jain M Eur J Pharmacol; 2013 Aug; 714(1-3):188-92. PubMed ID: 23810686 [TBL] [Abstract][Full Text] [Related]
12. A role for low hepatic copper concentrations in nonalcoholic Fatty liver disease. Aigner E; Strasser M; Haufe H; Sonnweber T; Hohla F; Stadlmayr A; Solioz M; Tilg H; Patsch W; Weiss G; Stickel F; Datz C Am J Gastroenterol; 2010 Sep; 105(9):1978-85. PubMed ID: 20407430 [TBL] [Abstract][Full Text] [Related]
13. Prefeeding with omega-3 fatty acids suppresses inflammation following hemorrhagic shock. Yang R; Harris WS; Vernon K; Thomas AM; Qureshi N; Morrison DC; Van Way CW JPEN J Parenter Enteral Nutr; 2010; 34(5):496-502. PubMed ID: 20852177 [TBL] [Abstract][Full Text] [Related]
14. Protective effect of bicyclol on tetracycline-induced fatty liver in mice. Yu HY; Wang BL; Zhao J; Yao XM; Gu Y; Li Y Toxicology; 2009 Jul; 261(3):112-8. PubMed ID: 19427351 [TBL] [Abstract][Full Text] [Related]
15. Rapid reduction of liver steatosis in omega3-depleted rats injected with a novel lipid emulsion. Carpentier YA; Peltier S; Portois L; Sebedio JL; Leverve X; Malaisse WJ Horm Metab Res; 2008 Dec; 40(12):875-9. PubMed ID: 18726832 [TBL] [Abstract][Full Text] [Related]
16. Mechanisms of Disease: hepatic steatosis in type 2 diabetes--pathogenesis and clinical relevance. Roden M Nat Clin Pract Endocrinol Metab; 2006 Jun; 2(6):335-48. PubMed ID: 16932311 [TBL] [Abstract][Full Text] [Related]
18. PPAR agonists treatment is effective in a nonalcoholic fatty liver disease animal model by modulating fatty-acid metabolic enzymes. Seo YS; Kim JH; Jo NY; Choi KM; Baik SH; Park JJ; Kim JS; Byun KS; Bak YT; Lee CH; Kim A; Yeon JE J Gastroenterol Hepatol; 2008 Jan; 23(1):102-9. PubMed ID: 18171348 [TBL] [Abstract][Full Text] [Related]
19. Effect of amount and types of dietary fat on intestinal bacterial 7 alpha-dehydroxylase and phosphatidylinositol-specific phospholipase C and colonic mucosal diacylglycerol kinase and PKC activities during stages of colon tumor promotion. Reddy BS; Simi B; Patel N; Aliaga C; Rao CV Cancer Res; 1996 May; 56(10):2314-20. PubMed ID: 8625306 [TBL] [Abstract][Full Text] [Related]